GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
Move at least an inch away from your last spot each time, or switch to a new zone entirely
This approach optimizes safety, speed, and efficiency during your shifts especially in high-acuity settings
When you are using the lowest dose possible of those medications, adherence to those lifestyle modifications is going to play a bigger role and will help you to stay on track, says Alkhaddo
However, long-term use is likely necessary, as stopping the medication often leads to weight regain
Retatrutide needs additional TRIUMPH trial results throughout 2026 before submitting for FDA approval in late 2026 or early 2027, with approval expected in late 2027 and launch in early 2028
